Vandetanib-d6
- CAS No.
- 1174683-49-8
- Chemical Name:
- Vandetanib-d6
- Synonyms
- Vandetanib-d6;N-(4-bromo-2-fluorophenyl)-6-(methoxy-d3)-7-[[1-(methyl-d3)-4-piperidinyl]methoxy]-4-quinazolinamine
- CBNumber:
- CB16197673
- Molecular Formula:
- C22H24BrFN4O2
- Molecular Weight:
- 475.36
- MDL Number:
- MFCD28343974
- MOL File:
- 1174683-49-8.mol
SAFETY
Risk and Safety Statements
| Symbol(GHS) |    GHS07,GHS08,GHS09 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Danger | |||||||||
| Hazard statements | H302-H360-H373-H410 | |||||||||
| Precautionary statements | P201-P202-P260-P264-P270-P273-P280-P301+P312-P330-P308+P313-P314-P391-P405-P501 | |||||||||
| NFPA 704 |
|
Vandetanib-d6 Chemical Properties,Uses,Production
Description
Vandetanib-d6 is intended for use as an internal standard for the quantification of vandetanib by GC- or LC-MS. Vandetanib is a multi-kinase inhibitor that inhibits VEGFR2, VEGFR3, VEGFR1, EGFR, PDGFRβ, Tie-2, and FGFR1 in cell-free assays (IC50s = 40, 110, 1,600, 500, 1,100, 2,500, and 3,600 nM, respectively).1,2 It also binds to 142 additional kinases in a panel of 442 kinases (Kds = 4.6-7,900 nM). Vandetanib (1 and 2.5 μM) induces apoptosis and cell cycle arrest at the G0/G1 phase in GEO colon and OVCAR-3 ovarian cancer cells.3 It inhibits proliferation of HAK1-B, KYN-2, and Huh7 hepatocarcinoma cells, as well as human umbilical vein endothelial cells (HUVECs), with IC50 values of 10, 8.1, 9.4, and 7.1 μM, respectively.4 Vandetanib (200 mg/kg) increases survival and decreases tumor angiogenesis and VEGFR2 levels in a D54MG glioblastoma mouse xenograft model.5 It reduces tumor growth in a variety of mouse xenograft models, including lung, colon, and breast cancer models, when administered at doses of 25, 50, and 100 mg/kg per day.1 Formulations containing vandetanib have been used in the treatment of medullary thyroid cancer.
References
1. Wedge, S.R., Ogilvie, D.J., Dukes, M., et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration Cancer Res. 62(16),4645-4655(2002).
2. Davis, M.I., Hunt, J.P., Herrgard, S., et al. Comprehensive analysis of kinase inhibitor selectivity Nat. Biotechnol. 29(11),1046-1051(2011).
3. Ciardiello, F., Caputo, R., Damiano, V., et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase Clin. Cancer Res. 9(4),1546-1556(2003).
4. Inoue, K., Torimura, T., Nakamura, T., et al. Vandetanib, an inhibitor of VEGF receptor-
5. Rich, J.N., Sathornsumetee, S., Keir, S.T., et al. ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors Clin. Cancer Res. 11(22),8145-8157(2005).
Vandetanib-d6 Preparation Products And Raw materials
Raw materials
Preparation Products
Vandetanib-d6 Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shanghai Hongye Biotechnology Co. Ltd | 400-9205774 | sales@glpbio.cn | China | 6870 | 58 |
| ChemeGen(Shanghai) Biotechnology Co.,Ltd. | 18818260767 | sales@chemegen.com | China | 11289 | 58 |
| Shanghai isotope chemical co.,ltd | 021-021-51600108 13062666369 | sales@chinaisotope.com | China | 4274 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 8747 | 58 |